1-甲基-2-甲酰苯并咪唑 | 3012-80-4

• 物质功能分类: 医药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 1-甲基-2-甲酰苯并咪唑
• 中文别名: 1-甲基-1H-苯并咪唑-2-甲醛；1-甲基-2-甲酸苯并咪唑
• 英文名称: 1-methyl-2-formyl-1H-benzimidazole
• 英文别名: 1-methyl-1H-benzo[d]imidazole-2-carbaldehyde；1-Methyl-2-formyl-benzimidazol；1-methyl-2-formylbenzimidazole；N-methylbenzimidazole-2-carbaldehyde；1-methyl-1H-benzimidazole-2-carbaldehyde；1-Methyl-1H-benzoimidazole-2-carbaldehyde；1-Methyl-benzimidazol-2-carboxaldehyd；2-Formyl-1-methyl-benzimidazol；1-methylbenzimidazole-2-carbaldehyde
• CAS: 3012-80-4
• 化学式: C₉H₈N₂O
• mdl: MFCD00142655
• 分子量: 160.175
• InChiKey: SIRPHJCQZYVEES-UHFFFAOYSA-N

物化性质

• 熔点：
  114-116 °C
• 沸点：
  286.07°C (rough estimate)
• 密度：
  1.1846 (rough estimate)
• 稳定性/保质期：

  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  存放于阴凉干燥处

SDS

Name:	1-Methyl-2-formylbenzimidazole 99+% Material Safety Data Sheet
Synonym:	Non
CAS:	3012-80-4

Section 1 - Chemical Product MSDS Name:1-Methyl-2-formylbenzimidazole 99+% Material Safety Data Sheet
Synonym:Non

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
3012-80-4	1-Methyl-2-formylbenzimidazole, 99+%	99+%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Get medical aid.
Skin:
In case of contact, flush skin with plenty of water. Remove contaminated clothing and shoes. Get medical aid if irritation develops and persists. Wash clothing before reuse.
Ingestion:
Get medical aid immediately. If swallowed, do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. Get medical aid.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Avoid contact with skin and eyes. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use process enclosure, local exhaust ventilation, or other engineering controls to control airborne levels.
Exposure Limits CAS# 3012-80-4: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: off-white to beige
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 119.0 - 122.0 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H8N2O
Molecular Weight: 160.18

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not currently available.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 3012-80-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-Methyl-2-formylbenzimidazole, 99+% - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 3012-80-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 3012-80-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 3012-80-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

1-甲基-2-甲酰苯并咪唑是一种咪唑类衍生物，可用作医药合成中间体。

制备

将N-甲基苯-1,2-二胺（13.5 g，85.4 mmol）和酒石酸（6.4 g，42.6 mmol）溶解在4 N HCl 水溶液（100 mL）中，并将该溶液在回流下搅拌过夜。冷却至室温后，通过真空过滤收集沉淀物并重新溶于水（200 mL）中，并用NH4OH 水溶液调节所得混合物的pH 至8。再次通过真空过滤收集沉淀物并干燥，得到6.86 g 所需产物1,2-双（1-甲基-1H-苯并[d]咪唑-2-基）乙烷-1,2-二醇，将其不经进一步纯化用于下一步骤。LC-MS：m/z 323（M+H+）。

将1,2-双（1-甲基-1H-苯并[d]咪唑-2-基）乙烷-1,2-二醇（4.9 g，15.2 mmol）和NaIO4（3.3 g，15.2 mmol）的溶液（150 mL）中逐滴加入3 N H2SO4 水溶液（18 mL）。在环境温度下搅拌过夜后，将混合物用Na2CO3水溶液调节至pH 8。通过真空过滤收集沉淀物并用水和乙醇洗涤。干燥固体，得到3.11 g 所需产物1-甲基-2-甲酰苯并咪唑。

急救措施

如果吸入1-甲基-2-甲酰苯并咪唑，请将患者移到新鲜空气处；如皮肤接触，应脱去污染的衣着，用肥皂水和清水彻底冲洗皮肤，如有不适感，就医；如眼睛接触，应分开眼睑，用流动清水或生理盐水冲洗，并立即就医；如果食入，立即漱口，禁止催吐，并立即就医。

反应信息

• 作为反应物：
  描述：

  1-甲基-2-甲酰苯并咪唑 在 叔丁基过氧化氢 、 碘 作用下， 以 水 、 乙腈 为溶剂， 以54%的产率得到1-甲基-2-碘-1H-苯并[d]咪唑
  参考文献：
  名称：

  Metal-free oxidative decarbonylative halogenation of fused imidazoles

  摘要：

  已经开发出一种高效策略，用于在温度控制下，在TBHP存在的情况下对卡巴醛咪唑融合杂环进行脱甲酰卤代反应。

  DOI：

  10.1039/d1nj04440k
• 作为产物：
  描述：

  1,2-二甲基苯并咪唑 在 selenium(IV) oxide 作用下， 反应 8.0h， 以53%的产率得到1-甲基-2-甲酰苯并咪唑
  参考文献：
  名称：

  Metal-free oxidative decarbonylative halogenation of fused imidazoles

  摘要：

  已经开发出一种高效策略，用于在温度控制下，在TBHP存在的情况下对卡巴醛咪唑融合杂环进行脱甲酰卤代反应。

  DOI：

  10.1039/d1nj04440k

文献信息

• Controlling Selectivity for Cycloadditions of Nitrones and Alkenes Tethered by Benzimidazoles: Combining Experiment and Theory
  作者：Liping Meng、Selina C. Wang、James C. Fettinger、Mark J. Kurth、Dean J. Tantillo

  DOI：10.1002/ejoc.200801211

  日期：2009.4

  Herein we describe a combined experimental/theoretical study on the effects of substituents on regio- and stereoselectivity in intramolecular 1,3-dipolar cycloadditions of nitrones and alkenes tethered by benzimidazoles. By employing a large substituent at position R2 or R3, complete selectivity was achieved for either the fused or bridged cycloadduct, respectively. In addition, these cycloadducts

  本文中，我们描述了结合的实验/理论研究，涉及取代基对苯并咪唑束缚的硝酮和烯烃的分子内1,3-偶极环加成反应中区域和立体选择性的影响。通过在位置R2或R3处使用大取代基，分别对稠合或桥接的环加合物实现了完全的选择性。另外，这些环加合物在所有检查的环加成物中均形成为单一非对映异构体。
• Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators
  申请人：Egle Ian

  公开号：US20090192169A1

  公开（公告）日：2009-07-30

  Compounds of Formula I: wherein A, B, D, L, R 1 , R 2 , R 3 , R 4 , m, and n are as defined for Formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.

  式I的化合物： 其中A、B、D、L、R1、R2、R3、R4、m和n的定义如描述中所定义。本发明还涉及制备这些化合物的方法，以及用于制备的新中间体，含有这些化合物的药物组合物，以及这些化合物在治疗中的应用。
• [EN] HETEROCYCLIC MGLU5 ANTAGONISTS<br/>[FR] ANTAGONISTES HÉTÉROCYCLIQUES DE MGLU5
  申请人：RECORDATI IRELAND LTD

  公开号：WO2011029633A1

  公开（公告）日：2011-03-17

  Compounds (I) (R1 is an optionally substituted C1-C13 heteromonocyclic, heterobicyclic or heterotri cyclic group containing from 1 to 5 heteroatoms selected from N, O and S; R2 is H, an optionally substituted monocyclic aromatic group, or a C1-C5 heteroaromatic group containing from 1 to 4 heteroatoms selected from N, O and S; R3 is an optionally substituted C1-C13 heteromonocyclic, heterobicyclic or heterotri cyclic group containing from 1 to 5 heteroatoms selected from N, O and S; an optionally substituted mono-, bi- or tricyclic C6-C14 aryl group, an optionally substituted C3-C6 cycloalkyl group, or an optionally substituted C3-C6 cycloalkenyl group; each R4, independently for each position capable of substitution, is H or C1-C6 alkyl; R5 is H, halogen or C1-C6 alkyl; m is 0, 1 or 2; n is 0, 1 or 2; p is 0, 1, 2, 3, 4, 5, or 6; and --- is an optional double bond) and their enantiomers, diastereomers, N-oxides and pharmaceutically acceptable salts, and pharmaceutical compositions containing them, are useful for the treatment of neuromuscular dysfunction of the lower urinary tract and also for the treatment of gastrooesophageal reflux disease; anxiety disorder; abuse, substance dependence and substance withdrawal disorders; neuropathic pain disorder, migraine and fragile X syndrome disorders.

  化合物（I）（其中R1为任选取代的含1至5个选自N、O和S的杂原子的C1-C13杂单环、杂双环或杂三环基团；R2为H、任选取代的单环芳香基团或含1至4个选自N、O和S的杂原子的C1-C5杂芳香基团；R3为任选取代的含1至5个选自N、O和S的杂原子的C1-C13杂单环、杂双环或杂三环基团，任选取代的单环、双环或三环C6-C14芳基团，任选取代的C3-C6环烷基团，或任选取代的C3-C6环烯基团；每个R4独立地为每个可取代位置上的H或C1-C6烷基；R5为H、卤素或C1-C6烷基；m为0、1或2；n为0、1或2；p为0、1、2、3、4、5或6；---为任选的双键）及其对映体、非对映体、N-氧化物和药学上可接受的盐，以及含有它们的药物组合物，可用于治疗下尿路神经肌肉功能障碍以及胃食管反流病；焦虑障碍；滥用、物质依赖和物质戒断障碍；神经性疼痛障碍、偏头痛和脆性X综合征障碍。
• HIV protease inhibiting compounds
  申请人：Flentge Charles A.

  公开号：US20110003827A1

  公开（公告）日：2011-01-06

  A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

  公开了一种具有以下公式的化合物，作为HIV蛋白酶抑制剂。还公开了抑制HIV感染的方法和组合物。
• [EN] HIV PROTEASE INHIBITING COMPOUNDS<br/>[FR] COMPOSES INHIBITEURS DE LA PROTEASE DU VIH
  申请人：ABBOTT LAB

  公开号：WO2005061487A1

  公开（公告）日：2005-07-07

  A compound of the formula (I) is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

  公开了一种公式(I)的化合物作为HIV蛋白酶抑制剂。还公开了用于抑制HIV感染的方法和组合物。